Cell Therapies names new CEO
Melbourne-based cellular therapy manufacturer and distributor Cell Therapies has appointed Dr Tim Oldham as its new CEO.
Oldham has more than a decade of experience in the life science sector, having held various positions including president of Asia-Pacific for Hospira and a series of senior management roles at Mayne Pharma. He is currently a director of Acrux (ASX:ACR) and iSonea (ASX:ISN).
Oldham is replacing founding CEO and managing director Ray Wood, who will continue on as a director.
Announcing the appointment, Cell Therapies said Oldham has been selected to implement the company’s aggressive growth plan.
“As late-stage and improved product numbers grow, scaling manufacturing up and out to reliably deliver a time-sensitive, patient-specific product with needle-to-needle control is becoming the challenge facing the cell-based therapies industry,” Oldham said.
“Cell Therapies’ unique expertise is solving this challenge. I am very excited to have been chosen to build on this expertise and grow our contract manufacturing and approved product distribution business into South-East Asia.”
The company is in talks to acquire distribution rights to a number of late-stage products, is upgrading its Melbourne manufacturing capacity and is in talks with a partner to develop a new facility in Malaysia.
The company licensed a second-generation cartilage repair product from Medipost in January 2013.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
